𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Telomere-mediated genomic instability and the clinico-pathological parameters in breast cancer

✍ Scribed by Anuradha Poonepalli; Birendranath Banerjee; Kalpana Ramnarayanan; Nallasivam Palanisamy; Thomas Choudary Putti; M. Prakash Hande

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
668 KB
Volume
47
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

A study was undertaken to correlate telomere dysfunction and genomic instability with the histopathological grades and the estrogen and progesterone receptor status in breast cancer. Sixty‐one archived breast tissues (38 cancer tissues and 23 paired normal tissues) were used in the study. The breast tumor tissues showed significantly shorter telomeres (7.7 kb) compared with the paired adjacent tissues (9.0 kb) by Southern blot analysis. Moreover, telomere shortening was more significant in Grade III tumors than in the Grade II tumors (P = 0.05). Quantitative fluorescence in situ hybridization on paraffin tissue sections revealed a similar trend in telomere shortening. Telomere attrition was associated with telomere dysfunction as revealed by the presence of significantly higher anaphase bridges in tumor cells which was tumor grade dependent. Furthermore, estrogen receptive negative tumors displayed higher anaphase and internuclear bridges. Selected samples from each grade showed greater genomic imbalances in the higher grades than the lower grade tumors as detected by array‐comparative genomic hybridization. Telomerase activity was found to be higher in the higher grades (Grade II and III) compared with the lower grade (Grade I). The average mRNA expression of TRF1 and POT1 was lower in the tumor tissues than in the normal tissues. Tankyrase 1 mRNA expression showed a grade‐dependent increase in tumor tissues and its expression was also high in estrogen and progesterone negative tumors. The data support the notion that telomere dysfunction might be of value as a marker of aggressiveness of the tumors in breast cancer patients. © 2008 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Telomerase activity in relation to p53 s
Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer
✍ Göran Roos; Pia Nilsson; Stefan Cajander; Niels-Hilmer Nielsen; Conny Arnerlöv; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 119 KB 👁 2 views

Cell cycle deregulation can occur at different levels in cancer. In human breast cancer it includes overexpression of cyclins D1 and E, down-regulation of cyclin-dependent kinase inhibitors and inactivation of the retinoblastoma and p53 tumor suppressor proteins. Telomerase activity is strongly asso

p53 allele losses, mutations and express
p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters
✍ A. M. Thompson; T. J. Anderson; A. Condie; J. Prosser; U. Chetty; D. C. Carter; 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 761 KB

The p53 locus on the short arm of chromosome I 7 at I7p 13. I was examined for loss of heterozygosity, mutation, rnRNA and protein expression in 60 primary breast cancers. Allele loss around the p53 locus was detected in 19/45 informative turnours (42%). p53 mutations in the evolutionarily conserved

The gene expression signature of genomic
The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome
✍ Jens K. Habermann; Jana Doering; Sampsa Hautaniemi; Uwe J. Roblick; Nana K. Bünd 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 899 KB

## Abstract Recently, expression profiling of breast carcinomas has revealed gene signatures that predict clinical outcome, and discerned prognostically relevant breast cancer subtypes. Measurement of the degree of genomic instability provides a very similar stratification of prognostic groups. We

Multiple mechanisms of action of ZR2002
Multiple mechanisms of action of ZR2002 in human breast cancer cells: A novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA
✍ Fouad Brahimi; Zakaria Rachid; Qiyu Qiu; James P. McNamee; Yu-Jiang Li; Ana M. T 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 276 KB 👁 2 views

## Abstract The mechanism of action of ZR2002, a chimeric amino quinazoline designed to possess mixed EGFR tyrosine kinase (TK) inhibitory and DNA targeting properties, was compared to those of ZR01, a reversible inhibitor of the same class and PD168393, a known irreversible inhibitor of EGFR. ZR20